Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $225.2 million.

  • Amylyx Pharmaceuticals' Cash & Equivalents rose 21344.81% to $225.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.2 million, marking a year-over-year increase of 21344.81%. This contributed to the annual value of $77.4 million for FY2024, which is 5452.96% down from last year.
  • Amylyx Pharmaceuticals' Cash & Equivalents amounted to $225.2 million in Q3 2025, which was up 21344.81% from $58.1 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Cash & Equivalents peaked at $247.8 million during Q2 2023, and registered a low of $50.2 million during Q4 2021.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Cash & Equivalents value was $92.6 million (recorded in 2022), while the average stood at $112.7 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Cash & Equivalents soared by 26737.84% in 2023 and then tumbled by 6972.92% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Cash & Equivalents (Quarter) stood at $50.2 million in 2021, then rose by 24.58% to $62.5 million in 2022, then surged by 172.21% to $170.2 million in 2023, then crashed by 54.53% to $77.4 million in 2024, then soared by 190.96% to $225.2 million in 2025.
  • Its Cash & Equivalents was $225.2 million in Q3 2025, compared to $58.1 million in Q2 2025 and $59.8 million in Q1 2025.